JP2020516615A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516615A5
JP2020516615A5 JP2019554976A JP2019554976A JP2020516615A5 JP 2020516615 A5 JP2020516615 A5 JP 2020516615A5 JP 2019554976 A JP2019554976 A JP 2019554976A JP 2019554976 A JP2019554976 A JP 2019554976A JP 2020516615 A5 JP2020516615 A5 JP 2020516615A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
protein
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019554976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516615A (ja
JP7789303B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026447 external-priority patent/WO2018187682A1/en
Publication of JP2020516615A publication Critical patent/JP2020516615A/ja
Publication of JP2020516615A5 publication Critical patent/JP2020516615A5/ja
Priority to JP2023208379A priority Critical patent/JP2024037834A/ja
Application granted granted Critical
Publication of JP7789303B2 publication Critical patent/JP7789303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019554976A 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質 Active JP7789303B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023208379A JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US62/482,963 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US62/607,706 2017-12-19
US201762611334P 2017-12-28 2017-12-28
US62/611,334 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023208379A Division JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Publications (3)

Publication Number Publication Date
JP2020516615A JP2020516615A (ja) 2020-06-11
JP2020516615A5 true JP2020516615A5 (cg-RX-API-DMAC7.html) 2021-05-13
JP7789303B2 JP7789303B2 (ja) 2025-12-22

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554976A Active JP7789303B2 (ja) 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Country Status (12)

Country Link
US (3) US10251933B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606542A4 (cg-RX-API-DMAC7.html)
JP (2) JP7789303B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003821A (cg-RX-API-DMAC7.html)
CN (1) CN110769844B (cg-RX-API-DMAC7.html)
AU (2) AU2018248324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059354A1 (cg-RX-API-DMAC7.html)
IL (1) IL269853A (cg-RX-API-DMAC7.html)
MX (2) MX393998B (cg-RX-API-DMAC7.html)
SG (1) SG11201909334TA (cg-RX-API-DMAC7.html)
TW (1) TWI797116B (cg-RX-API-DMAC7.html)
WO (1) WO2018187682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3773644A4 (en) * 2018-04-06 2021-06-02 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
WO2021035129A1 (en) * 2019-08-21 2021-02-25 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
US11666629B2 (en) * 2020-01-10 2023-06-06 National Taipei University Of Technology Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
PT3307288T (pt) * 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2018223051A1 (en) 2017-06-02 2018-12-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Similar Documents

Publication Publication Date Title
JP2020516615A5 (cg-RX-API-DMAC7.html)
Kim et al. NOD-like receptors in infection, immunity, and diseases
AU2020339348B2 (en) Akkermansia muciniphila EB-AMDK27 strain and use thereof
CN110049760A (zh) 用于治疗炎性疾病的组合物及其用途以及益生菌组合物
US20240066095A1 (en) Proteins for the treatment of epithelial barrier function disorders
US12168677B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2015007216A1 (zh) 多肽、编码该多肽的dna分子、载体、制备方法及应用
JP2011225596A5 (cg-RX-API-DMAC7.html)
JP2014523906A5 (cg-RX-API-DMAC7.html)
KR20240026882A (ko) 락토바실러스 뮤코세 및 수용성 식이섬유의 조합물을 사용한 방법 및 조성물
CN117187096A (zh) 用于改善肠屏障功能的大肠杆菌菌株及其应用
CN113286604A (zh) 治疗炎症性疾病的蛋白质
US12186364B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2013004069A1 (zh) 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用
JP7469812B2 (ja) 抗微生物特性を有する化合物
JP2009263307A (ja) 炎症性腸疾患の予防・治療剤
EP3538132A1 (en) Rectal insulin for treatment of inflammatory bowel diseases
CN116350748A (zh) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
CN117017978A (zh) 香豆素类化合物在制备预防新冠病毒感染引起的肺炎药物中的应用
JP7229519B2 (ja) 血管新生促進剤
CN107951898A (zh) mir-146a-5p在治疗肠易激综合征内脏高敏感性中的应用
Warner et al. Alcohol-induced liver injury is attenuated by human beta defensin in experimental ALD via improvements in the gut-liver axis
CN110638803A (zh) Dencichine在制备治疗炎性肠病药物中的用途
KR20200110684A (ko) 궤양성 대장염을 앓고 있는 환자를 치료하기 위한 조성물, 및 약물로서의 조성물의 용도
CN114874311A (zh) 防御肽及其制备方法和应用